# CITATION REPORT List of articles citing

Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure

DOI: 10.1016/j.jacc.2012.01.077 Journal of the American College of Cardiology, 2012, 60, 1031-42.

**Source:** https://exaly.com/paper-pdf/53799650/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
309	Ultrafiltration in decompensated heart failure with cardiorenal syndrome. <b>2012</b> , 367, 2296-304		577
308	Reconsidering ultrafiltration in the acute cardiorenal syndrome. <b>2012</b> , 367, 2351-2		15
307	Kardiorenales Syndrom. <b>2013</b> , 8, 298-307		
306	Contrast-induced acute kidney injury following coronary angiography: a cohort study of hospitalized patients with or without chronic kidney disease. <b>2013</b> , 28, 1463-71		40
305	Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. <b>2013</b> , 6, 1087-94		22
304	Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction. <b>2013</b> , 169, 379-84		43
303	Dialysis initiation: what's the rush?. <b>2013</b> , 26, 650-7		35
302	Worsening renal function in patients with acute decompensated heart failure treated with ultrafiltration: predictors and outcomes. <b>2013</b> , 19, 787-94		3
301	Is there still a role for ultrafiltration in the management of acute heart failure? CARRESS and beyond. <b>2013</b> , 10, 185-9		4
300	Cardiac resynchronization therapy in CKD: a systematic review. <b>2013</b> , 8, 1293-303		25
299	HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin II-induced lymphocyte activation. <b>2013</b> , 62, 310-6		15
298	Cystatin C as a predictor of mortality and cardiovascular morbidity after cardiac resynchronization therapy. <b>2013</b> , 77, 2751-6		12
297	Role of Pulsatile Hemodynamics in Acute Heart Failure: Implications for Type 1 Cardiorenal Syndrome. <b>2013</b> , 1, 89-96		2
296	Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study. <b>2014</b> , 9, e112313		29
295	Identification and predicting short-term prognosis of early cardiorenal syndrome type 1: KDIGO is superior to RIFLE or AKIN. <b>2014</b> , 9, e114369		29
294	Deleterious Effects of Increased Intra-Abdominal Pressure on Kidney Function. <b>2014</b> , 2014, 1-15		9
293	Editorial: cardio-metabolic complications: current perspective and future developments. <b>2014</b> , 20, 130	3-4	

## (2014-2014)

292	Relationship between coronary artery disease and C-reactive protein levels in NSTEMI patients with renal dysfunction: a retrospective study. <b>2014</b> , 15, 152	11
291	Acute heart failure: acute cardiorenal syndrome and role of aggressive decongestion. <b>2014</b> , 37, 773-8	6
290	Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. <b>2014</b> , 18, R134	42
289	A low-dose <b>I</b> I-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. <b>2014</b> , 127, 105-13	21
288	Management of the Nephrotic Patient: Treatment of ECF Volume Expansion Due to Nephrotic Syndrome in Adults. <b>2014</b> , 165-169	
287	Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective. <b>2014</b> , 2014, 313718	9
286	Fluid removal in acute heart failure: diuretics versus devices. <b>2014</b> , 20, 478-83	7
285	Erratum. <b>2014</b> , 20, 376-376.e32	
284	Renal dysfunction in acute congestive heart failure: a common problem for cardiologists and nephrologists. <b>2014</b> , 19, 699-708	13
283	Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom. <b>2014</b> , 8, 26-35	4
283	Dialyse- und Ultrafiltrationsverfahren bei kardiorenalem Syndrom. <b>2014</b> , 8, 26-35  Responsiveness to loop diuretics in heart failure. <b>2014</b> , 35, 1235-7	9
282	Responsiveness to loop diuretics in heart failure. <b>2014</b> , 35, 1235-7  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <b>2014</b> ,	9
282	Responsiveness to loop diuretics in heart failure. <b>2014</b> , 35, 1235-7  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <b>2014</b> , 35, 1284-93	9 205
282 281 280	Responsiveness to loop diuretics in heart failure. 2014, 35, 1235-7  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 2014, 35, 1284-93  [Diagnosis of systolic and diastolic heart failure]. 2014, 55, 647-54  Ultrafiltration veinoveineuse isolä dans la prise en charge de lihsuffisance cardiaque congestive	9 205
282 281 280 279	Responsiveness to loop diuretics in heart failure. 2014, 35, 1235-7  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 2014, 35, 1284-93  [Diagnosis of systolic and diastolic heart failure]. 2014, 55, 647-54  Ultrafiltration veinoveineuse isolā dans la prise en charge de līhsuffisance cardiaque congestive et du syndrome cardiorāal. 2014, 23, 603-617	9 205 2
282 281 280 279 278	Responsiveness to loop diuretics in heart failure. 2014, 35, 1235-7  Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 2014, 35, 1284-93  [Diagnosis of systolic and diastolic heart failure]. 2014, 55, 647-54  Ultrafiltration veinoveineuse isol® dans la prise en charge de l¶suffisance cardiaque congestive et du syndrome cardiorBal. 2014, 23, 603-617  Le syndrome cardiorBal: diagnostic, physiopathologie et prise en charge. 2014, 23, 585-594	9 205 2

274	Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF. <b>2014</b> , 16, 330	6
273	[Organ damage and cardiorenal syndrome in acute heart failure]. 2014, 142 Suppl 1, 26-31	9
272	The acute cardiorenal syndrome type I: considerations on physiology, epidemiology, and therapy. <b>2014</b> , 11, 382-92	12
271	Acute kidney injury in the elderly: Only the tip of the iceberg. <b>2014</b> , 5, 7-12	13
270	Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. <b>2014</b> , 20, 611-22	32
269	Calling for targeted trials in cardiorenal syndromes. <b>2014</b> , 64, 10-2	1
268	Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin. <b>2014</b> , 19, 267-84	26
267	Serum albumin levels predict clinical outcomes in chronic kidney disease (CKD) patients undergoing cardiac resynchronization therapy. <b>2014</b> , 53, 555-61	14
266	The hemodynamic and nonhemodynamic crosstalk in cardiorenal syndrome type 1. <b>2014</b> , 4, 103-12	26
265	Admission hyperglycemia is an independent predictor of acute kidney injury in patients with acute myocardial infarction. <b>2014</b> , 78, 1475-80	41
264	Complete recovery of acute kidney injury in native kidney following heart kidney transplantation. <b>2015</b> , 9, 109-112	
263	Cardiorenal Syndrome Type 1: Activation of Dual Apoptotic Pathways. <b>2015</b> , 5, 306-15	14
262	Efficacy and safety of ultrafiltration in decompensated heart failure patients with renal insufficiency. <b>2015</b> , 56, 319-23	7
261	Combined biomarker analysis for risk of acute kidney injury in patients with ST-segment elevation myocardial infarction. <b>2015</b> , 10, e0125282	28
260	De novo acute heart failure and acutely decompensated chronic heart failure. <b>2015</b> , 112, 298-310	22
259	Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis. <b>2015</b> , 2015, 391790	43
258	The failing heart: a bad case of the 'flu'. <b>2015</b> , 2015,	
257	Kidney disease in heart failure: the importance of novel biomarkers for type 1 cardio-renal syndrome detection. <b>2015</b> , 10, 543-54	13

256 Assessment of Vascular Function by Using Cardiac Catheterization. **2015**, 127-141

255	Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. <b>2015</b> , 68, 426-35	20
254	Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2433-48	117
253	Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. <b>2015</b> , 154, 1-12	27
252	Pro-Apoptotic Effects of Plasma from Patients with Cardiorenal Syndrome on Human Tubular Cells. <b>2015</b> , 41, 474-84	17
251	Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. <b>2015</b> , 3, 97-107	75
250	Novel markers and therapies for patients with acute heart failure and renal dysfunction. <b>2015</b> , 128, 312.e1-22	9
249	Congenital Heart Disease. <b>2015</b> ,	
248	What physicians need to know about renal function in outpatients with heart failure. <b>2015</b> , 131, 130-8	12
247	Team-Based Care for Managing Noncardiac Conditions in Patients with Heart Failure. <b>2015</b> , 11, 419-29	7
246	Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review. <b>2015</b> , 5, 48-60	21
245	Effect of estimated plasma volume reduction on renal function for acute heart failure differs between patients with preserved and reduced ejection fraction. <b>2015</b> , 8, 527-32	30
244	SEdrome cardiorrenal en la insuficiencia cardiaca aguda: revisando paradigmas. <b>2015</b> , 68, 426-435	28
243	Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors. <b>2015</b> , 5, 105-15	18
242	One-year survival and renal function recovery of acute kidney injury patients with chronic heart failure. <b>2015</b> , 5, 40-7	8
241	Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs. <b>2015</b> , 14, 12-24	7
240	A Clinical Approach to the Acute Cardiorenal Syndrome. <b>2015</b> , 31, 685-703	18
239	Serelaxin a novel treatment for acute heart failure. <b>2015</b> , 8, 549-57	3

238	Prediction of mortality using quantification of renal function in acute heart failure. 2015, 201, 650-7	20
237	Is Preoperative Endothelial Dysfunction a Potentially Modifiable Risk Factor for Renal Injury Associated With Noncardiac Surgery?. <b>2015</b> , 29, 1220-8	3
236	Biomarkers and physiopathology in the cardiorenal syndrome. <b>2015</b> , 443, 100-7	26
235	Cardio-Renal Clinical Challenges. 2015,	1
234	Efficacy of extracorporeal ultrafiltration in patients with diuretic-resistant heart failure. <b>2016</b> , 2016,	2
233	Effectiveness of Ultrafiltration in Patients with Congestive Heart Failure. 2016,	
232	Veno-arterial extracorporeal membrane oxygenation (VA ECMO) in postcardiotomy cardiogenic shock: how much pump flow is enough?. <b>2016</b> , 8, E1444-E1448	11
231	Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease. <b>2016</b> , 2016, 8761475	13
230	Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats. <b>2016</b> , 10, 1581-8	8
229	Nutritional Status is Associated with Inflammation and Predicts a Poor Outcome in Patients with Chronic Heart Failure. <b>2016</b> , 23, 713-27	69
228	The role of cardiac dysfunction in multiorgan dysfunction. <b>2016</b> , 29, 172-7	6
227	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <b>2016</b> , 18, 588-98	173
226	Extracorporeal Membrane Oxygenation and the Kidney. <b>2015</b> , 6, 50-60	62
225	Advances in the Management of Acute Cardiorenal Syndrome in China: Biomarkers for Predicting Development and Outcomes. <b>2017</b> , 2, 145-150	6
224	Combination of Urinary Biomarkers Improves Early Detection of Acute Kidney Injury in Patients With Heart Failure. <b>2016</b> , 80, 1017-23	27
223	Type 4 cardiorenal syndrome. <b>2016</b> , 35, 601-616	4
222	Alterations in blood pressure, antioxidant status and caspase 8 expression in cobalt chloride-induced cardio-renal dysfunction are reversed by Ocimum gratissimum and gallic acid in Wistar rats. <b>2016</b> , 36, 27-37	21
221	Surgical Decision Making. <b>2016</b> ,	2

220	[Acute cardiorenal syndromes]. <b>2016</b> , 111, 341-58	3
219	Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome. <b>2016</b> , 11, 1536-44	47
218	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations: The AKINESIS Study. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1420-1431 15.1	57
217	Type 4 cardiorenal syndrome. <b>2016</b> , 35, 601-616	8
216	Case report: severe bradycardia, a reversible cause of "Cardio-Renal-Cerebral Syndrome". <b>2016</b> , 17, 162	4
215	Difficult Decisions in Cardiothoracic Surgery: Acute Cardiogenic Shock. <b>2016</b> , 165-175	
214	Goal-Directed Heart Failure Care in Patients With Chronic Kidney Disease and End-Stage Renal Disease. <b>2016</b> , 4, 662-3	1
213	Excessively High Hydration Volume May Not Be Associated With Decreased Risk of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention in Patients With Renal Insufficiency. <b>2016</b> , 5,	28
212	Chronic kidney disease and worsening renal function in acute heart failure: different phenotypes with similar prognostic impact?. <b>2016</b> , 5, 534-548	26
211	Target organ damage in acute heart failure. <b>2016</b> , 216, 99-105	
210	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. <b>2016</b> , 2, 119-30	15
209	Contemporary Treatment of Acute Heart Failure. <b>2016</b> , 58, 367-78	17
208	Focus on renal congestion in heart failure. <b>2016</b> , 9, 39-47	52
207	Pathophysiology of acute heart failure: a world to know. <b>2016</b> , 216, 38-46	7
206	Traitement de recours dans linsuffisance cardiaque avancë. <b>2016</b> , 25, 226-238	
205	Pathophysiology of acute heart failure: A world to know. <b>2016</b> , 216, 38-46	4
204	Target organ damage in acute heart failure. <b>2016</b> , 216, 99-105	2
203	Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. <b>2016</b> , 42, 147-63	113

202	Pathophysiology and clinical evaluation of acute heart failure. <b>2016</b> , 13, 28-35	86
201	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <b>2016</b> , 22, 26-32	34
200	Pulmonary Hypertension in the Intensive Care Unit. <b>2016</b> , 31, 369-85	24
199	Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. <b>2017</b> , 233, 1-11	7
198	Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. <b>2017</b> , 19, 760-767	39
197	Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness. <b>2017</b> , 43, 151-162	4
196	Heart Failure. <b>2017</b> , 93-141	
195	Initiation and Cessation Timing of Renal Replacement Therapy in Patients with Type 1 Cardiorenal Syndrome: An Observational Study. <b>2017</b> , 7, 118-127	2
194	Ensuring Patient Safety During the Transition to ESRD. <b>2017</b> , 37, 194-208	4
193	Reply to 'Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure'. <b>2017</b> , 40, 900-901	
192	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <b>2017</b> , 135, e1054-e1091	274
191	Ultrafiltration versus intravenous loop diuretics in patients with acute decompensated heart failure: a meta-analysis of clinical trials. <b>2017</b> , 72, 132-141	3
190	Safe Hydration Volume to Prevent Contrast-induced Acute Kidney Injury and Worsening Heart Failure in Patients With Heart Failure and Preserved Ejection Fraction After Cardiac Catheterization. <b>2017</b> , 70, 168-175	3
0		
189	Insights into cardiorenal interactions in acute decompensated heart failure. <b>2017</b> , 32, 203-208	3
189	Urinary [TIMP-2] [[IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. <b>2017</b> , 40, 485-491	23
	Urinary [TIMP-2] [[IGFBP7] for risk prediction of acute kidney injury in decompensated heart	
188	Urinary [TIMP-2] [[IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure. <b>2017</b> , 40, 485-491	23

184	Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. <b>2017</b> , 313, H715-H721	23
183	The Transition From Hypertension to Heart Failure: Contemporary Update. <b>2017</b> , 5, 543-551	160
182	SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys. <b>2017</b> , 14, 331-337	8
181	C-terminal fragment of agrin (CAF) levels predict acute kidney injury after acute myocardial infarction. <b>2017</b> , 18, 202	5
180	Aging Male Spontaneously Hypertensive Rat as an Animal Model for the Evaluation of the Interplay between Contrast-Induced Acute Kidney Injury and Cardiorenal Syndrome in Humans. <b>2016</b> , 7, 1-10	7
179	Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system. <b>2017</b> , 12, 23-30	1
178	Effect of the renal natriuretic peptide, ularitide, alone or combined with Vasopeptidase inhibitor, Omapatrilat, on experimental volume overload-induced congestive heart failure in rats (Ularitide/Omapatrilat in Congestive Heart Failure)Peer review under responsibility of Alexandria University Faculty of Medicine.View all notes Available online 11 June 2016View all notes. 2017, 53, 135-149	
177	Comparison of myocardial damage among dogs at different stages of clinical leishmaniasis and dogs with idiopathic chronic kidney disease. <b>2017</b> , 221, 1-5	11
176	Relaxin Ameliorates Renal Fibrosis and Expression of Endothelial Cell Transition Markers in Rats of Isoproterenol-Induced Heart Failure. <b>2017</b> , 40, 960-966	11
175	Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction - Prospective Randomized Controlled Study. <b>2017</b> , 81, 740-747	25
174	The Physiopathology of Cardiorenal Syndrome: A Review of the Potential Contributions of Inflammation. <b>2017</b> , 4,	16
173	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. <b>2017</b> , 12, e0177303	29
172	Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function. <b>2017</b> , 17, 202	23
171	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <b>2018</b> , 24, 428-438	18
170	Changes in kidney tissue and effects of erythropoietin after acute heart failure. 2018, 93, 340-353	7
169	Combination of Mean Platelet Volume/Platelet Count Ratio and the APACHE II Score Better Predicts the Short-Term Outcome in Patients with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy. <b>2018</b> , 43, 479-489	10
168	Prognostic value of nutrition status in the response of cardiac resynchronization therapy. <b>2018</b> , 18, 133-139	1
167	Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. <b>2018</b> , 254, 189-194	19

166	The Association Between Pulsatile Portal Flow and Acute Kidney Injury after Cardiac Surgery: A Retrospective Cohort Study. <b>2018</b> , 32, 1780-1787	29
165	Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. <b>2018</b> , 4, 43-50	7
164	Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure. <b>2018</b> , 33, 163-169	7
163	Cardiorenal Syndrome Type 1: Definition, Etiopathogenesis, Diagnostics and Treatment. <b>2018</b> , 19, 73-80	
162	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <b>2018</b> , 37, 696-705	16
161	Noninvasive Identification of Renal Hypoxia in Experimental Myocardial Infarctions of Different Sizes by Using BOLD MR Imaging in a Mouse Model. <b>2018</b> , 286, 129-139	8
160	Is the mean platelet volume a predictive marker of a high in-hospital mortality of acute cardiorenal syndrome patients receiving continuous renal replacement therapy?. <b>2018</b> , 97, e11180	3
159	Cardiorenal Syndrome: An Overview. <b>2018</b> , 25, 382-390	50
158	Pathophysiological Mechanisms in Cardiorenal Syndrome. <b>2018</b> , 25, 400-407	9
157	Epidemiology of Cardiorenal Syndrome. <b>2018</b> , 25, 391-399	15
157 156	Epidemiology of Cardiorenal Syndrome. <b>2018</b> , 25, 391-399  Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. <b>2018</b> , 25, 408-417	15 8
156	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. <b>2018</b> , 25, 408-417	8
156 155	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. <b>2018</b> , 25, 408-417  Toward Precision Medicine in the Cardiorenal Syndrome. <b>2018</b> , 25, 418-424  Management of acute heart failure: Contribution of daily bedside echocardiographic assessment on	8
156 155 154	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. 2018, 25, 408-417  Toward Precision Medicine in the Cardiorenal Syndrome. 2018, 25, 418-424  Management of acute heart failure: Contribution of daily bedside echocardiographic assessment on therapy adjustment with impact measure on the 30-day readmission rate (JECICA). 2018, 12, 103-108  Combination of Amino-Terminal Pro- BNP, Estimated GFR, and High-Sensitivity CRP for Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. 2018, 7, e009162  Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1. 2018, 8, 321-331	8 3 1
156 155 154 153	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. 2018, 25, 408-417  Toward Precision Medicine in the Cardiorenal Syndrome. 2018, 25, 418-424  Management of acute heart failure: Contribution of daily bedside echocardiographic assessment on therapy adjustment with impact measure on the 30-day readmission rate (JECICA). 2018, 12, 103-108  Combination of Amino-Terminal Pro- BNP, Estimated GFR, and High-Sensitivity CRP for Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. 2018, 7, e009162  Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with	8 3 1 6
156 155 154 153	Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. 2018, 25, 408-417  Toward Precision Medicine in the Cardiorenal Syndrome. 2018, 25, 418-424  Management of acute heart failure: Contribution of daily bedside echocardiographic assessment on therapy adjustment with impact measure on the 30-day readmission rate (JECICA). 2018, 12, 103-108  Combination of Amino-Terminal Pro- BNP, Estimated GFR, and High-Sensitivity CRP for Predicting Cardiorenal Syndrome Type 1 in Acute Myocardial Infarction Patients. 2018, 7, e009162  Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1. 2018, 8, 321-331  Prevalence and predictors of left ventricular dysfunction among patients with chronic kidney disease attending Muhimbili National Hospital in Tanzania — a cross-sectional study.	8 3 1 6

148	Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk. <b>2018</b> , 44, 1447-1459	46
147	Worsening or pseudo-worseningDrenal function? The prognostic value of hemoconcentration in patients admitted with acute heart failure. <b>2018</b> , 37, 595-602	3
146	Urine Cofilin-1 Detection for Predicting Type 1 Cardiorenal Syndrome in the Coronary Care Unit: A Gold Nanoparticle- and Laser-Based Approach. <b>2018</b> , 8, 302-310	2
145	Tidal peritoneal dialysis versus ultrafiltration in type 1 cardiorenal syndrome: A prospective randomized study. <b>2019</b> , 42, 684-694	7
144	Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. <b>2019</b> , 68, 825-839	20
143	Implication of Acute Kidney Injury in Heart Failure. <b>2019</b> , 15, 463-476	6
142	Plasma Lipopolysaccharide Concentrations in Cardiorenal Syndrome Type 1. <b>2019</b> , 9, 308-315	1
141	Kidney-based in vitro models for drug-induced toxicity testing. <b>2019</b> , 93, 3397-3418	40
140	Management of Chronic Kidney Disease and End-Stage Kidney Disease Patients in the Intensive Care Unit. <b>2019</b> , 1286-1292.e3	1
139	Treating the Cardiorenal Syndrome: A Sledgehammer for a Needle's Work?. <b>2019</b> , 25, 935-936	
138	Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure: A Novel Predictor Candidate for Cardiorenal Syndrome. <b>2019</b> , 8, e011468	11
137	Management of Refractory Ascites for Liver Transplant Candidates: A Novel Cell-free and Concentrated Ascites Reinfusion Therapy. <b>2019</b> , 51, 2740-2744	1
136	Three-dimensional speckle-tracking echocardiography for evaluating myocardial motion in patients with cardiorenal syndrome. <b>2019</b> , 47, 412-418	1
135	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <b>2019</b> , 25, 654-665	14
134	Cardiorenal Syndrome Type 1. <b>2019</b> , 677-689.e2	
133	Lipopolysaccharide in systemic circulation induces activation of inflammatory response and oxidative stress in cardiorenal syndrome type 1. <b>2019</b> , 32, 803-810	4
132	Prognostic Impact of Worsening Renal Function in Hospitalized Heart Failure Patients With Preserved Ejection Fraction: A Report From the JASPER Registry. <b>2019</b> , 25, 631-642	6
131	Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials. <b>2019</b> , 9, e025537	7

130	Heart-kidney interactions: mechanistic insights from animal models. <b>2019</b> , 316, F974-F985	13
129	Characteristics of coronary artery disease in chronic kidney disease. <b>2019</b> , 23, 725-732	20
128	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <b>2019</b> , 139, e840-e878	301
127	Common laboratory parameters as indicators of multi-organ dysfunction in acute heart failure. <b>2019</b> , 21, 751-753	
126	Cardiorenal Syndrome and Heart Failure-Challenges and Opportunities. 2019, 35, 1208-1219	21
125	Interactive and potentially independent roles of renin-angiotensin-aldosterone system blockade and the development of cardiorenal syndrome type 1 on in-hospital mortality among elderly patients admitted with acute decompensated congestive heart failure. <b>2019</b> , 12, 33-48	1
124	Heart-Kidney Cross-Talk. <b>2019</b> , 664-670.e3	1
123	I-MIBG cardiac sympathetic imaging provides further insight into cardiorenal interactions in systolic heart failure patients. <b>2021</b> , 28, 2123-2125	
122	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <b>2019</b> , 21, 1586-1595	12
121	Acute kidney injury. <b>2019</b> , 394, 1949-1964	388
121	Acute kidney injury. 2019, 394, 1949-1964  B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. 2019, 21, 1553-1560	388
	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute	Ĭ
120	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <b>2019</b> , 21, 1553-1560  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of	9
120 119	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <b>2019</b> , 21, 1553-1560  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. <b>2019</b> , 9, 1-7	9
120 119 118	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. <b>2019</b> , 21, 1553-1560  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. <b>2019</b> , 9, 1-7  Treatment patterns of patients with acute heart failure who develop acute kidney injury. <b>2019</b> , 6, 45-52  Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. <b>2019</b> ,	9 20 9
120 119 118	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. 2019, 21, 1553-1560  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. 2019, 9, 1-7  Treatment patterns of patients with acute heart failure who develop acute kidney injury. 2019, 6, 45-52  Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. 2019, 109, 658-670	9 20 9
120 119 118 117	B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. 2019, 21, 1553-1560  Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. 2019, 9, 1-7  Treatment patterns of patients with acute heart failure who develop acute kidney injury. 2019, 6, 45-52  Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat. 2019, 109, 658-670  Cardiorenal Syndrome Type 1. 2019, 216-222.e3  Echocardiographic parameters of patients in the intensive care unit undergoing continuous renal	9 20 9 23

### (2020-2020)

112	Clinical impacts of changes of renal function during hospitalization depend on grades of renal dysfunction in acute decompensated heart failure. <b>2020</b> , 35, 509-520	2
111	Mechanisms of kidney dysfunction in the cirrhotic patient: Non-hepatorenal acute-on-chronic kidney damage considerations. <b>2020</b> , 19, 145-152	4
110	The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. <b>2020</b> , 25, 31-42	25
109	Cardiorenal Syndrome in Heart Failure. <b>2020</b> ,	1
108	The role of the kidney in acute and chronic heart failure. <b>2020</b> , 25, 107-118	9
107	Incidence and implications of acute kidney injury in patients hospitalized with acute decompensated heart failure. <b>2020</b> , 15, 421-428	5
106	Intraoperative and Early Postoperative Management of Heart Transplantation: Anesthetic Implications. <b>2020</b> , 34, 2189-2206	4
105	Impact of a contrast media volume control device on acute kidney injury rate in patients with acute coronary syndrome. <b>2021</b> , 98, 76-84	1
104	Kidney Disease in the Cardiac Catheterization Laboratory. <b>2020</b> ,	
103	Prognostic Significance of Chronic Kidney Disease (CKD-EPI Equation) and Anemia in Patients with Chronic Heart Failure Secondary to Chagas Cardiomyopathy. <b>2020</b> , 2020, 6417874	1
102	Investigation of the relationship between sensorineural hearing loss and associated comorbidities in patients with chronic kidney disease: A nationwide, population-based cohort study. <b>2020</b> , 15, e0238913	2
101	Renoprotective effect of tolvaptan in patients with new-onset acute heart failure. <b>2020</b> , 7, 1764-1770	6
100	Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients. <b>2020</b> , 21, 207	13
99	Implications of Kidney Disease in the Cardiac Patient. <b>2020</b> , 9, 265-278	1
98	Acute cardiorenal syndrome in acute heart failure: focus on renal replacement therapy. <b>2020</b> , 9, 802-811	6
97	Renal kinetics in acute heart failure. <b>2020</b> , 7,	1
96	Activation of the Nitric Oxide Pathway and Acute Myocardial Infarction Complicated by Acute Kidney Injury. <b>2020</b> , 10, 85-96	4
95	Comparison of pancreatic and renal blood flow in a canine tachycardia-induced cardiomyopathy model. <b>2020</b> , 82, 836-845	3

94	Predictors for non-delayed discharge after transcatheter aortic valve replacement: utility of echocardiographic parameters. <b>2021</b> , 37, 47-58	О
93	Value of Renal Vascular Doppler Sonography in Cardiorenal Syndrome Type 1. <b>2021</b> , 40, 321-330	1
92	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. <b>2021</b> , 8, 183-203	11
91	Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients: a meta-analysis. <b>2021</b> , 26, 577-585	3
90	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study. <b>2021</b> , 23, 58-67	5
89	Histopathological changes in the pancreas due to decreased pancreatic blood flow in a canine tachycardia-induced cardiomyopathy model. <b>2021</b> , 83, 780-783	O
88	Deciphering key genes in cardio-renal syndrome using network analysis. <b>2021</b> , 17, 86-100	Ο
87	Body volume is the major determinant of worsening renal function in acutely decompensated heart failure with reduced left ventricular ejection fraction. <b>2021</b> ,	
86	Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study. <b>2021</b> , 14, e007048	10
85	Forced diuresis oriented by point-of-care ultrasound in cardiorenal syndrome type 5 due to light chain myeloma-The role of hepatic venogram: A case report. <b>2021</b> , 9, 2453-2459	
84	Preliminary algorithm for a personalized diagnosis of cardiovascular disease and dependent renal complications using decision tree. <b>2021</b> , 87, 175-189	
83	Serum creatinine as a predictor of mortality in patients readmitted to the intensive care unit after cardiac surgery: a retrospective cohort study in China. <b>2021</b> , 13, 1728-1736	2
82	Evidence-Based Management of Acute Heart Failure. <b>2021</b> , 37, 621-631	5
81	Cardiorenal Syndrome. <b>2021</b> , 37, 335-347	3
80	Incidence and outcomes of acute kidney injury stratified by cardiogenic shock severity. <b>2021</b> , 98, 330-340	4
79	Cardio-renal syndrome type 1 is associated with hospital-acquired disability in patients with acute decompensated heart failure. <b>2021</b> , 28, 197-204	
78	Arginine Vasopressin as an Important Mediator of Fluctuations in the Serum Creatinine Concentration Under Decongestion Treatment in Heart Failure Patients. <b>2021</b> , 3, 324-332	1
77	Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome. <b>2021</b> , 26, 611-618	Ο

### (2015-2021)

76	Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes. <b>2021</b> , 8,	1
75	Early implementation of renal replacement therapy after lung transplantation does not impair long-term kidney function in patients with idiopathic pulmonary arterial hypertension. <b>2021</b> ,	3
74	IGF IIRtriggered pathological manifestations in the heart aggravate renal inflammation in STZ-induced type-I diabetes rats. <b>2021</b> , 13, 17536-17547	0
73	Evidence based review of management of cardiorenal syndrome type 1. <b>2021</b> , 11, 187-198	1
72	Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved. <b>2021</b> , 10,	1
71	Predictors of acute kidney injury in patients with acute decompensated heart failure in emergency departments in China. <b>2021</b> , 49, 3000605211016208	O
70	Editorial. <b>2021</b> , 1-2	
69	The Role of Cell-Free Plasma DNA in Patients with Cardiorenal Syndrome Type 1. <b>2021</b> , 1-8	Ο
68	Cardio-renal syndrome. <b>2016</b> , 5,	8
67	[Myocardial fibrosis: Current aspects of the problem]. 2017, 89, 88-93	10
66	[Myocardial fibrosis: Current aspects of the problem]. 2017, 89, 88-93  Renal effects of vasodilators in acute heart failure. 2013, 03, 8-17	10
66	Renal effects of vasodilators in acute heart failure. <b>2013</b> , 03, 8-17	1
66	Renal effects of vasodilators in acute heart failure. <b>2013</b> , 03, 8-17  Heart failure and acute renal dysfunction in the cardiorenal syndrome. <b>2020</b> , 20, 146-150  Unravelling the role of hub genes associated with cardio renal syndrome through an integrated	1
66 65 64	Renal effects of vasodilators in acute heart failure. <b>2013</b> , 03, 8-17  Heart failure and acute renal dysfunction in the cardiorenal syndrome. <b>2020</b> , 20, 146-150  Unravelling the role of hub genes associated with cardio renal syndrome through an integrated bioinformatics approach. <b>2021</b> , 25, 101382	1
66 65 64	Renal effects of vasodilators in acute heart failure. 2013, 03, 8-17  Heart failure and acute renal dysfunction in the cardiorenal syndrome. 2020, 20, 146-150  Unravelling the role of hub genes associated with cardio renal syndrome through an integrated bioinformatics approach. 2021, 25, 101382  Chronic Kidney Disease: Cardiovascular Complications. 2014, 589-601  Reactive Oxygen Species in the Pathogenesis of Chronic Kidney Disease: Lessons Derived from	1
66 65 64 63	Renal effects of vasodilators in acute heart failure. 2013, 03, 8-17  Heart failure and acute renal dysfunction in the cardiorenal syndrome. 2020, 20, 146-150  Unravelling the role of hub genes associated with cardio renal syndrome through an integrated bioinformatics approach. 2021, 25, 101382  Chronic Kidney Disease: Cardiovascular Complications. 2014, 589-601  Reactive Oxygen Species in the Pathogenesis of Chronic Kidney Disease: Lessons Derived from Diabetic Nephropathy. 2014, 2675-2703	1

58	Acute Heart Failure Syndromes. <b>2017</b> , 81-162	
57	Cardiogenic Shock. <b>2017</b> , 163-207	
56	Acute Decompensated Heart Failure: Treatment (\$\frac{1}{2}\text{pecific Therapies. 2017}, 219-284	
55	Acute Decompensated Heart Failure: Classification, Epidemiology and Pathophysiology. <b>2017</b> , 149-170	2
54	Acute Decompensated Heart Failure: Treatment with Guideline Directed Medical Therapy and Discharge Planning. <b>2017</b> , 285-308	
53	Cardiorenal Syndrome (CRS). <b>2017</b> , 371-401	
52	PROGNOSTIC VALUE OF RENAL DYSFUNCTION AND THE IMBALANCE OF BODY AQUATIC ENVIRONMENTS IN PATIENTS WITH ACUTE CORONARY PATHOLOGY. <b>2017</b> , 21, 39-45	1
51	Biomarker of Myocardial Stress sST2 in Patients with Acute Myocardial Infarction with ST-Segment Elevation. <b>2018</b> , 3, 55-59	
50	Incidence, Risk Factors and Prognosis of Contrast-Induced Acute Kidney Injury in Acute Heart Failure Patients Undergoing Coronary Angiography. <b>2019</b> , 1, 72	2
49	The Kidney in Diastolic Dysfunction. <b>2019</b> , 718-721.e1	
48	Determinants and Risks Factors of Renal Failure in Patients with Heart Failure in Cardiology Department of CHU Sylvanus Olympio of Lomé (Togo). <b>2019</b> , 09, 65-76	
47	Inflammatio us a procoagulant state for appearing thrombus in patient with secondary dilated cardiomyopathy. <b>2019</b> , 12, 82-82	
46	Pathophysiology of Cardio-Renal Syndrome: Autonomic Mechanisms. <b>2020</b> , 35-50	
45	Inflammation as a procoagulant state for thrombus manifestation in a patient with secondary dilated cardiomyopathy. <b>2019</b> , 14, 245-246	
44	Evaluation of biomarkers effi ciency in predictive and early diagnostics of acute kidney damage in acute coronary syndrome (pilot study). <b>2019</b> , 23, 61-72	
43	Panoramic Dominance of the Immune System in Cardiorenal Syndrome Type I. <b>2020</b> , 12, e9869	3
42	Risk Factors for AKI Development in Acute Decompensated Heart Failure. <b>2020</b> , 69-83	
41	Prognostic value of worsening renal function in patients with acute decompensated heart failure with preserved ejection fraction and its association with increased inflammatory state. <b>2020</b> , 6, 157	

40 A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. **2020**, 449-461

39	Diuretic Resistance in Heart Failure. <b>2021</b> , 29, 73-81	2
38	Implications of Chronic Kidney Disease on the Epidemiology of Cardiovascular Disease. <b>2021</b> , 1-5	
37	Obesity. <b>2021</b> , 267-278	
36	Nephrology Inpatient Consultative Approach in Patients with Cardiovascular Disease. <b>2021</b> , 369-382	
35	Type 1 Cardio-Renal Syndrome. <b>2021</b> , 59-73	
34	pplication of myocardial damage and heart failure biomarkers in preventive and early diagnosis of aki in acute coronary syndrome. <b>2020</b> , 24, 28-39	
33	Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease. <b>2014</b> , 18, 315-8	7
32	Detection and evaluation of renal biomarkers in a swine model of acute myocardial infarction and reperfusion. <b>2015</b> , 8, 8336-47	5
31	Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction. <b>2016</b> , 8, 239-45	5
30	High uric acid level increases the risk of acute kidney injury in acute coronary syndrome patients. <b>2021</b> , 12, 323-326	
29	Predialysis serum lactate levels could predict dialysis withdrawal in Type 1 cardiorenal syndrome patients <b>2022</b> , 44, 101232	1
28	Endpoints in Heart Failure Drug Development 2022, 8, e01	О
27	Heart Failure. <b>2022</b> , 103-155	
26	Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure <b>2022</b> , 1	О
25	Interleukin-10 attenuates renal injury after myocardial infarction in diabetes 2022,	1
24	Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment <b>2021</b> , 8, 760152	1
23	Mitochondrial Dysfunction: An Emerging Link in the Pathophysiology of Cardiorenal Syndrome <b>2022</b> , 9, 837270	0

	Different Renal Function Patterns in Patients With Acute Heart Failure: Relationship With Outcome and Congestion <b>2022</b> , 9, 779828	
21	Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. 10.34067/KID.0006372021	Ο
20	Beyond the Cardiorenal Syndrome: Pathophysiological Approaches and Biomarkers for Renal and Cardiac Crosstalk <b>2022</b> , 12,	5
19	Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat <b>2022</b> , 148, 112745	О
18	Samchulkunbi-Tang Alleviates Vascular Endothelial Disorder and Renal Dysfunction in Nitric Oxide-Deficient Hypertensive Rats <b>2021</b> , 2021, 8443952	
17	Hemoconcentration of creatinine minimally contributes to changes in creatinine during treatment of decompensated heart failure. 10.34067/KID.0007582021	O
16	Management of Extracellular Fluid Volume in the Nephrotic Patient. 2022, 393-400	
15	Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics. <b>2022</b> , 9,	О
14	Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials.	0
	Parkartina Efforts and Parkartin Asiana Call by Maintaining Conding Output in Coning Hand Enilyse	
13	Protective Effect on Pancreatic Acinar Cell by Maintaining Cardiac Output in Canine Heart Failure Model With Decreased Pancreatic Blood Flow. 9,	
13		1
	Model With Decreased Pancreatic Blood Flow. 9,	1
12	Model With Decreased Pancreatic Blood Flow. 9,  The Diabetic Cardiorenal Nexus. 2022, 23, 7351	1
12	Model With Decreased Pancreatic Blood Flow. 9,  The Diabetic Cardiorenal Nexus. 2022, 23, 7351  Extracorporeal organ support and the kidney. 2,  Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart	
12 11 10	Model With Decreased Pancreatic Blood Flow. 9,  The Diabetic Cardiorenal Nexus. 2022, 23, 7351  Extracorporeal organ support and the kidney. 2,  Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world. 2022, 44, 1486-1497  Cardiorenal syndrome type I recovery following heart rate correction: Cardiac output is not only	
12 11 10	Model With Decreased Pancreatic Blood Flow. 9,  The Diabetic Cardiorenal Nexus. 2022, 23, 7351  Extracorporeal organ support and the kidney. 2,  Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world. 2022, 44, 1486-1497  Cardiorenal syndrome type I recovery following heart rate correction: Cardiac output is not only stroke volume. 2022, 10,  Diagnosing Arterial Stiffness in Pregnancy and Its Implications in the Cardio-Renal-Metabolic Chain.	1
12 11 10 9 8	Model With Decreased Pancreatic Blood Flow. 9,  The Diabetic Cardiorenal Nexus. 2022, 23, 7351  Extracorporeal organ support and the kidney. 2,  Urine N-terminal pro-B-type natriuretic peptide and plasma proenkephalin are promising biomarkers for early diagnosis of cardiorenal syndrome type 1 in acute decompensated heart failure: a prospective, double-center, observational study in real-world. 2022, 44, 1486-1497  Cardiorenal syndrome type I recovery following heart rate correction: Cardiac output is not only stroke volume. 2022, 10,  Diagnosing Arterial Stiffness in Pregnancy and Its Implications in the Cardio-Renal-Metabolic Chain. 2022, 12, 2221  Total Testosterone as a Specific Marker of Acute Kidney Injury in Male Patients With Myocardial	1 O

#### CITATION REPORT

4	Is It Possible to Analyze Kidney Functions, Electrolytes and Volemia Using Artificial Intelligence?. <b>2022</b> , 12, 3131	О
3	Impact of the degree of worsening renal function and B-type natriuretic peptide on the prognosis of patients with acute heart failure. 10,	O
2	Retrospective analyses of the outcomes among hospitalized liver cirrhosis patients with heart failure and COVID-19 infection: Insight from the National Inpatient Sample. <b>2023</b> , 27, 100271	О
1	Contemporary laboratory assessment of acute cardiorenal syndrome for early diagnosis: A call for action. <b>2023</b> , 261, 75-84	O